Yes, all hands on deck soon (now maybe) makes sense … if, “if”, they are ready for the full forward push .. below I’ll paste a link to an article along with a KEY point by the ceo, when reading it’s very apparent they WANTED to be under the radar as to be able to quietly gain proof of concept while generating capital and get all their preverbal ducks in a row so to speak … it’s seems like NOW all pillars are sound and foundations laid, research completing status / complete, etc .. don’t get me wrong while im very optimistic I’m also very pragmatic, I’m heavily invested and curious to hear what Tuesday will bring .. but, in the mean time, read the below - the dr ceo has been very transparent with each step along the way thus far, IMO that is … have a great weekend, enjoy the read below - it truly is worth the read or re-read if you’ve seen before … Looking forward to Tuesday! ———- I posted the below before on this board, but I feel the excerpt quoted especially addresses the concern over why the company hasn’t been blasting not seeking loud pr thus far …
“Creating, producing and selling consumer products was never our primary focus; Quanta's Muscle Rub was simply a means to an end - proof of concept and a revenue driver in a small emerging market as our business model took shape. Fundamentally, Quanta will be a licensing concern designed to collaborate with large brands to improve product quality and the profit margins of existing and new products. But the market needed proof and we chose to start in the under-developed category of CBD because of its speed to market.
Understandably, we met the same initial hurdles every start-up encounters. In addition to simply explaining quantum mechanics, we had no track record of success from a business standpoint. The immediate goal was to prove our model was defensible. Hence, we chose CBD as a launch category. This market provided protection from industry titans that may have felt threatened by such a powerful technology while allowing us to drive profits during R&D.
Over the last two years, we have developed and sold products largely to the medical industry, along with some consumer retail. This effort was designed to drive revenue and to prove the concept of our model: that polarizing a single ingredient can produce a demonstrably superior product that consumers find safe and effective (establish consumer appetite).”
News 
Market Data 
Discover 
AI
